Interim PET/CT-adapted Use of PD-1 Inhibitor Combined With De-escalated Chemotherapy-AVD in Classic Hodgkin Lymphoma
18. juli 2026 opdateret af: Xiao-Jun Huang, Peking University People's Hospital
A Prospective Single-institution Phase II Study of Interim PET/CT-adapted PD-1 Inhibitor Addition to First-line Chemotherapy for Unfavorable Stage II and Stage III/IV Classical Hodgkin Lymphoma to Omit High-dose Chemotherapy and Radiotherapy
This study enrolls newly diagnosed unfavorable stage II /stage III-IV classical Hodgkin lymphoma patients.
All participants receive 2 cycles ABVD induction chemotherapy, then stratified by interim PET-CT Deauville score for differentiated treatment: standard ABVD for DS1-3, AVD plus Sintilimab for DS4, salvage chemotherapy plus autologous stem cell transplant for DS5.
The primary goal is to assess 2-year progression-free survival and compare long-term survival and toxicities across subgroups, to verify whether Sintilimab addition can avoid high-dose chemo-radiotherapy for DS4 patients.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
130
Fase
- Fase 2
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Beijing, Kina
- Peking University People's Hospital
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ingen
Beskrivelse
Inclusion Criteria:
- Age ≥ 18 years old;
- Histologically confirmed newly diagnosed classical Hodgkin lymphoma (cHL);
- Eligible to receive standard frontline ABVD induction chemotherapy for 2 cycles;
- Able to complete interim PET-CT (iPET2) scan after 2 cycles ABVD for Deauville score stratification;
- Adequate bone marrow, hepatic and renal function to tolerate chemotherapy and immunotherapy;
- Life expectancy ≥ 6 months at enrollment;
- Willing to comply with scheduled treatment, imaging follow-up and laboratory tests;
Exclusion Criteria:
- Prior systemic anti-lymphoma therapy, including chemotherapy, radiation, anti-PD-1/PD-L1 immunotherapy or stem cell transplantation;
- Severe irreversible organ dysfunction (cardiac, pulmonary, hepatic, renal) that cannot tolerate cytotoxic chemotherapy;
- Known hypersensitivity to doxorubicin, bleomycin, vinblastine, dacarbazine or sintilimab;
- Active severe infection (e.g., uncontrolled sepsis, active tuberculosis, HIV infection);
- Pregnant or breastfeeding female patients;
- Inability to complete serial PET-CT imaging due to contraindications such as severe contrast allergy
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: iPET2 Stratified ABVD-Based Treatment Arm
All patients receive 2 cycles of frontline ABVD induction chemotherapy first, then treatment is stratified by iPET2 Deauville score: DS 1-3: Complete standard full-course ABVD chemotherapy; DS 4: AVD combined with Sintilimab maintenance to avoid high-dose chemo-radiotherapy; DS 5: Salvage intensive chemotherapy followed by autologous stem cell transplantation |
Combination chemotherapy containing Doxorubicin, Bleomycin, Vinblastine and Dacarbazine, 2 cycles as uniform frontline induction treatment for all eligible patients.
Anti-PD-1 monoclonal antibody Sintilimab, combined with AVD chemotherapy and given as maintenance therapy for patients with iPET2 Deauville Score 4 to avoid high-dose chemo-radiotherapy.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
2-year Progression-Free Survival (PFS)
Tidsramme: 2 years after completion of all assigned treatment
|
Time from study enrollment to first disease progression or death from any cause, stratified by iPET2 Deauville score subgroups.
Disease progression is confirmed by radiological imaging evaluation.
|
2 years after completion of all assigned treatment
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
5-year Progression-Free Survival (PFS)
Tidsramme: 5 years after completion of all assigned treatment
|
Long-term progression-free survival up to 5 years after treatment completion, compared across iPET2 stratified subgroups.
|
5 years after completion of all assigned treatment
|
|
Incidence of All-Grade and Grade 3-5 Adverse Events
Tidsramme: Throughout treatment period and 5-year long-term follow-up
|
Rate of hematological, non-hematological and Sintilimab-related immune adverse events graded per CTCAE v5.0 during treatment and follow-up.
|
Throughout treatment period and 5-year long-term follow-up
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
1. februar 2019
Primær færdiggørelse (Faktiske)
28. februar 2026
Studieafslutning (Faktiske)
28. februar 2026
Datoer for studieregistrering
Først indsendt
18. juli 2026
Først indsendt, der opfyldte QC-kriterier
18. juli 2026
Først opslået (Faktiske)
22. juli 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
22. juli 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
18. juli 2026
Sidst verificeret
1. juli 2026
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- PET2-cHL-PD1
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
UBESLUTET
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .